tirzepatide cvot trial SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS-CVOT Shows Mounjaro Surpasses Trulicity

Liraglutide treatment may affect renin and aldosterone release

what their toxicities, adverse effects, or interactions with other medications are

For example, loading without rest for 48 h under physiological cycle conditions caused significant net oxidation of glutathione in cartilage, which decreased the protection of glutathione against further oxidative stress (Zhu et al., 2020)

Overexpression of the heme oxygenase gene in renal cell carcinoma

Researchers have found that SGLT2 inhibitors which are used to treat type 2 diabetes may help lower a persons risk of developing kidney stones

Diabetes (1997) 46:173342